 Figure 1. Change in FVC from Baseline of Bexotegrast 320 mg Over 12 Weeks in INTEGRIS-IPF; Mixed Model Repeat Measures Analysis Modified Intent to Treat Population Figure 2. Proportion of Participants with FVCpp Decline 10 Intent to Treat Population Figure 3. Circulating PRO-C3 and Integrin beta-6 Biomarker Levels Change from Baseline at 4- ... The post Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and... 